4-Methyl-amphetamine: A health threat for recreational amphetamine users

Journal of Psychopharmacology

Volumn 27, Issue 9, 2013, Pages 817-822

  Blanckaert, P ^a   Van Amsterdam, J G C ^b   Brunt, T M ^c   Van Den Berg, J D J ^d   Van Durme, F ^e   Maudens, K ^f   Van Bussel, J C H ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^d NETHERLANDS FORENSIC INSTITUTE   (Netherlands)

^e National Institute of Criminalistics and Criminology   (Belgium)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

4 methylamphetamine; amphetamines; neuropharmacology; new psychoactive substances; toxicology

Indexed keywords

4 METHYLAMPHETAMINE; AMPHETAMINE; ILLICIT DRUG; RECREATIONAL DRUG;

ARTICLE; BELGIUM; CAUSE OF DEATH; DOPAMINERGIC ACTIVITY; DRUG FATALITY; DRUG INTOXICATION; DRUG MARKETING; DRUG MISUSE; DRUG STRUCTURE; DRUG SYNTHESIS; EPIDEMIOLOGICAL MONITORING; HEALTH HAZARD; HUMAN; NETHERLANDS; NONHUMAN; PRIORITY JOURNAL; RECREATION; SEROTONINERGIC TRANSMISSION; TOXICOLOGY;

4-METHYLAMPHETAMINE; AMPHETAMINES; NEUROPHARMACOLOGY; NEW PSYCHOACTIVE SUBSTANCES; TOXICOLOGY;

AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; DOPAMINE AGENTS; DRUG USERS; HUMANS; METHAMPHETAMINE; NETHERLANDS; SEROTONIN AGENTS; SUBSTANCE ABUSE DETECTION;

EID: 84883443396     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113487950     Document Type: Article

References (36)

1. Aldous FA, Barras BC, Brewster K, et al. Structure-activity relationships in psychotomimetic phenylalkylamines. J Med Chem. 1974 ; 17: 1100-1111
2. Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 ; 29: 719-732
3. Baselt RC Disposition of Toxic Drugs and Chemicals in Man, Ninth Edition. Seal Beach, CA: Biomedical Publications ; 2011 :
4. Baumann MH, Clark RD, Woolverton WL, et al. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther. 2011 ; 337: 218-225
5. Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: An update. Arch Toxicol. 2012 ; 86: 1167-1231
6. Ciechomska M, Wozniakiewics M, Wietecha-Posluszny R. Activity and biotransformation of three synthetic "Legal Highs": Mephedrone, Methylone and 3,4-Methylenodioxypyrovalerone. Probl Forensic Sci. 2012 ; 89: 71-85
7. De Letter EA, Piette MH, Lambert WE, et al. Amphetamines as potential inducers of fatalities: A review in the district of Ghent from 1976-2004. Med Sci Law. 2006 ; 46: 37-65
8. Docherty JR, Green AR. The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol. 2010 ; 160: 1029-1044
9. National Report 2011: Belgium. European Monitoring Centre for Drugs and Drug Addiction ; 2012a :
10. National Report 2011: Netherlands. European Monitoring Centre for Drugs and Drug Addiction ; 2012b :
11. Fellows EJ, Bernheim F. The effects of a number of aralkylamines on the oxidation of tyramine by amine oxidase. J Pharmacol Exp Ther. 1950 ; 100: 94-99
12. Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007 ; 47: 681-698
13. Gelvin EP, McGavack TH. 2-Amino-1-(p-methylphenyl)-propane (Aptrol) as an anorexigenic agent in weight reduction. N Y State J Med. 1952 ; 52: 223-226
14. Green AR, Mechan AO, Elliot JM, et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstacy"). Pharmacol Rev. 2003 ; 55: 463-508
15. Jaehne EJ, Salem A, Irvine RJ. Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. Psychopharmacology (Berl). 2007 ; 194: 41-52
16. Jones AW, Holmgren A. Abnormally high concentrations of amphetamine in blood of impaired drivers. J Forensic Sci. 2005 ; 50: 1215-1220
17. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs 24. CMAJ. 2001 ; 165: 917-928
18. Kimmel HL, Manvich DF, Blough BE, et al. Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacol Biochem Behav. 2009 ; 94: 278-284
19. Kita JM, Kile BM, Parker LE, et al. In vivo measurement of somatodendritic release of dopamine in the ventral tegmental area. Synapse. 2009 ; 63: 951-960
20. Maickel RP, Johnson SA. Effects of various anorexigenic agents on open field behavior of rats. Res Commun Chem Pathol Pharmacol. 1973 ; 6: 733-739
21. Marsh DF, Herring DA. The pharmacological activity of the ring methyl substituted phenisopropylamines. J Pharmacol Exp Ther. 1950 ; 100: 298-308
22. Meyer MR, Wilhelm J, Peters FT, et al. Beta-keto amphetamines: Studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem. 2010 ; 397: 1225-1233
23. Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav. 2002 ; 71: 837-844
24. Riva M, Kabir NM, Pirola C, et al. [Relation of the anorexigenic, hyperthermal, and excitomotor activity of compounds structurally related to amphentamine]. Farmaco Sci. 1969 ; 24: 238-248
25. Ross SB, Ogren SO, Renyi AL. Substituted amphetamine derivatives. I. Effect on uptake and release of biogenic monoamines and on monoamine oxidase in the mouse brain. Acta Pharmacol Toxicol (Copenh). 1977 ; 41: 337-352
26. Rothman RB, Baumann MH. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci. 2006 ; 1074: 245-260
27. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001 ; 39: 32-41
28. Schifano F, Corkery J, Naidoo V, et al. Overview of amphetamine-type stimulant mortality data - UK, 1997-2007. Neuropsychobiology. 2010 ; 61: 122-130
29. Shankaran M, Gudelsky GA. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl). 1999 ; 147: 66-72
30. Sprague JE, Banks ML, Cook VJ, et al. Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther. 2003 ; 305: 159-166
31. Youth Attitudes on Drugs. Analytical Report. Luxembourg: European Commission ; 2011 :
32. Uitgaansonderzoek in Vlaanderen. 2009 ;:
33. Van Der Poel A, Doekhie J, Verdunnen J, et al Utrecht: Bonger Instituut; Trimbos Insitituut ; 2010 :
34. Vanthomme K, Walckiers D, Van Oyen H. Belgian health-related data in three international databases. Arch Public Health. 2011 ; 69: 6
35. Verschraagen M, Maes A, Ruiter B, et al. Post-mortem cases involving amphetamine-based drugs in The Netherlands. Comparison with driving under the influence cases. Forensic Sci Int. 2007 ; 170: 163-170
36. Wee S, Anderson KG, Baumann MH, et al. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs 5323. J Pharmacol Exp Ther. 2005 ; 313: 848-854